Core Viewpoint - JD Health (06618) shows strong revenue and profit growth in Q3 2025, driven by the expansion of medical insurance payments, offline service development, and deepening AI medical applications, reinforcing its leading position in the pharmaceutical e-commerce sector [1] Performance - In Q3 2025, JD Health achieved revenue of 17.12 billion yuan, a year-on-year increase of 28.7% from 13.3 billion yuan, accelerating from 23.7% growth in Q2 [2] - Operating profit reached 1.243 billion yuan, a significant year-on-year increase of 125.3% [2] - Non-IFRS operating profit was 1.378 billion yuan, up 59.9% year-on-year, while non-IFRS net profit was 1.902 billion yuan, reflecting a 42.4% increase [2] - The net profit margin improved from 10.1% in the first half of the year to 11.1% [2] Operational Data - JD Health has expanded online medical insurance payments to nearly 200 million people, a substantial increase from over 100 million year-on-year [2] - The number of platform merchants exceeded 150,000, growing by over 50,000 since the end of 2024 [2] - The "AI Jingyi" intelligent service user base surpassed 50 million [2] - Offline service expansion included the opening of three new health check centers and a significant increase in overall order volume, which grew over four times year-on-year [2] Strategic Cooperation - In Q3 2025, JD Health signed strategic cooperation agreements with major pharmaceutical companies such as Eli Lilly, Innovent Biologics, and Bayer China, enhancing its supply chain advantages in high-end pharmaceuticals [3] Medical AI Applications - JD Health partnered with Huazhong University of Science and Technology to create a leading smart outpatient service platform, promoting the comprehensive application of AI products in hospital outpatient services [4] - The collaboration aims to establish a full-process AI accompaniment system to enhance patient experience and improve medical resource utilization [4] Investment Recommendations - JD Health's leading position in pharmaceutical e-commerce is expected to be bolstered by ongoing online medical insurance payment policies and the scaling of AI services [5] - Revenue forecasts for 2025-2027 are projected at 71 billion, 82.9 billion, and 95.5 billion yuan, with adjusted net profits of 6.3 billion, 7.4 billion, and 8.5 billion yuan respectively [5] - The current stock price corresponds to P/E ratios of 32, 28, and 24 times for the respective years [5]

Core Viewpoint - JD Health (06618) shows strong revenue and profit growth in Q3 2025, with accelerating growth rates, supported by expanded insurance payment coverage, offline service expansion, and deepening AI medical applications, reinforcing its leading position in the pharmaceutical e-commerce sector [1] Performance - In Q3 2025, JD Health achieved revenue of 17.12 billion yuan, a year-on-year increase of 28.7% from 13.3 billion yuan, with growth accelerating from 23.7% in Q2 [2] - Operating profit reached 1.243 billion yuan, a significant year-on-year increase of 125.3% [2] - Non-IFRS operating profit was 1.378 billion yuan, up 59.9% year-on-year, while Non-IFRS net profit was 1.902 billion yuan, reflecting a 42.4% increase [2] Operational Data - JD Health continues to expand insurance payment coverage and upgrade service networks, with online insurance payments benefiting nearly 200 million people, a substantial increase from over 100 million year-on-year [3] - As of June 30, 2025, the platform had over 150,000 merchants, an increase of over 50,000 from the end of 2024 [3] - The "AI Jingyi" intelligent service user base surpassed 50 million, and offline service expansion included the opening of new medical beauty stores and health check centers [3] Strategic Cooperation - In Q3 2025, JD Health signed strategic cooperation agreements with several well-known pharmaceutical companies, including Eli Lilly and Bayer China, to strengthen its position in the high-end drug supply chain [4] Medical AI Applications - JD Health partnered with Huazhong University of Science and Technology to create a leading smart outpatient service platform, promoting the application of AI products in hospital outpatient services [5] - The AI accompaniment system aims to enhance patient experience and improve medical resource utilization, with potential for replication in more hospital settings [5] Investment Recommendations - JD Health's leading position in pharmaceutical e-commerce is solid, with ongoing online insurance payment policies and the scaling of AI services expected to provide short- to medium-term catalysts [6] - Revenue forecasts for 2025-2027 are projected at 71 billion, 82.9 billion, and 95.5 billion yuan, with adjusted net profits of 6.3 billion, 7.4 billion, and 8.5 billion yuan, respectively [6] - The current stock price corresponds to P/E ratios of 32, 28, and 24 times for the respective years [6]

Core Viewpoint - UBS report indicates that JD Health's third-quarter performance exceeded expectations in both revenue and profit, driven by strong growth in pharmaceutical sales and a significant rebound in health product business [1] Revenue Growth - JD Health's revenue growth accelerated from 24.5% in the first half of the year to 28.7% in the third quarter, attributed to robust pharmaceutical sales and a low comparative base in the third quarter of 2024 [1] Profit Forecast - UBS raised JD Health's profit forecasts for 2025 to 2027 by 4% to 13%, reflecting confidence in the company's growth trajectory [1] Target Price Adjustment - The target price for JD Health was increased from HKD 78.5 to HKD 85, implying a 1.25 times price-to-earnings growth rate by 2027 [1] Investment Rating - UBS maintains a "Buy" rating for JD Health, indicating a positive outlook for the company's future performance [1]

Core Viewpoint - UBS has raised JD Health's (06618) profit forecasts for 2025 to 2027 by 4% to 13%, adjusting the target price from HKD 78.5 to HKD 85, implying a 1.25x growth rate for 2027 [1] Group 1: Financial Performance - JD Health's Q3 revenue and profit exceeded expectations, with revenue growth accelerating from 24.5% in the first half of the year to 28.7% in Q3 [1] - The strong growth in revenue is attributed to robust sales of pharmaceuticals and a significant rebound in health products, along with a relatively low base in Q3 2024 [1] Group 2: Sales Growth Drivers - Pharmaceutical sales growth is estimated to maintain a strong rate of approximately 30% in Q3, driven by chronic disease medications and innovative drugs [1] - The company's online-to-offline (O2O) strategy is progressing steadily, contributing to the overall sales growth [1]

Core Viewpoint - UBS has raised JD Health's (06618) profit forecasts for 2025 to 2027 by 4% to 13%, increasing the target price from HKD 78.5 to HKD 85, implying a 1.25x growth rate for 2027, while maintaining a "Buy" rating [1] Group 1: Financial Performance - JD Health's Q3 revenue and profit exceeded expectations, with revenue growth accelerating from 24.5% in the first half of the year to 28.7% in Q3 [1] - The strong growth in revenue is attributed to robust sales in pharmaceuticals and a significant rebound in health products, alongside a relatively low base in Q3 2024 [1] Group 2: Sales Growth Drivers - Pharmaceutical sales growth is estimated to maintain a strong rate of approximately 30% in Q3, with even faster growth in chronic disease medications and innovative drugs [1] - The company's online-to-offline (O2O) strategy is steadily advancing, contributing to the overall sales performance [1]

Core Viewpoint - Nomura's report indicates that JD Health's Q3 performance is strong, with total revenue growing by 29% year-on-year to reach 17 billion yuan, driven by sales of pharmaceuticals, nutritional products, and medical devices [1] Group 1: Financial Performance - JD Health's total revenue for Q3 reached 17 billion yuan, representing a 29% year-on-year increase [1] - Sales of pharmaceuticals and nutritional products both grew by 30%, while medical device sales increased by approximately 15% [1] - The reported revenue exceeded Nomura's estimates by 4% [1] Group 2: Market Trends - JD Health's pharmaceutical sales benefit from the shift of prescriptions from hospitals to outpatient settings, alongside an accelerated online penetration rate for drug sales [1] - This trend is expected to continue until 2026 [1] Group 3: Earnings Forecast and Valuation - Nomura has raised JD Health's earnings forecasts for the fiscal years 2025 and 2026 by 9% and 8% respectively [1] - The "Buy" rating is maintained, with the target price increased from 72 HKD to 80 HKD, based on a 32 times adjusted price-to-earnings ratio for the fiscal year 2026 [1] - The adjustment reflects potential profitability upside due to enhanced operational leverage [1]

Core Viewpoint - The collaboration between JD Health and Himalaya aims to enhance diabetes management through digital and intelligent health services, improving the quality of life for diabetes patients [1][4]. Group 1: Diabetes Prevalence and Management Needs - As of 2024, the number of diabetes patients in China has reached 148 million, with projections suggesting it will approach 170 million by 2030 [3]. - Many diabetes patients are unaware of their condition, highlighting the need for increased awareness and early screening [3]. - Key preventive measures for workplace populations include weight control, maintaining a positive mindset, and regular exercise [3]. Group 2: Healthcare Services and Collaborations - JD Health has partnered with over 800 pharmaceutical companies focused on diabetes medication, providing comprehensive health services from medication to management [4]. - The JD Internet Hospital has seen a 40% year-on-year increase in consultations related to diabetes as of November 1 [4]. - JD Health and Sanofi have established the "Feifan Guardian - Diabetes Care Center" to offer online consultations, medication guidance, and nutritional advice [4]. Group 3: Future Directions - JD Health plans to continue enhancing chronic disease management services towards intelligent, personalized, and full-cycle approaches, contributing to the "Healthy China 2030" initiative [5].

Core Viewpoint - The company reported better-than-expected performance for Q3 2025, driven by strong growth in pharmaceutical categories, with revenue reaching 17.12 billion yuan (+28.7% YoY) and non-IFRS net profit at 1.902 billion yuan (+42.4% YoY) [1] Development Trends - The growth in original research drug categories continues to drive revenue, with foreign pharmaceutical companies enhancing their presence in the outpatient market and increasing investments in online channels and digital marketing [1] - The company's strong performance in Q3 2025 is primarily attributed to the growth in pharmaceutical categories, particularly in original research drugs, which aligns with the trends observed in the first half of 2025 [1] - Strategic cooperation agreements were signed with major pharmaceutical companies such as Eli Lilly, Innovent Biologics, and Bayer China during Q3 2025, reinforcing the company's unique business model of launching new drugs across all networks [1] Profitability Performance - The company achieved a non-IFRS operating profit of 1.378 billion yuan (+59.9% YoY) in Q3 2025, with a corresponding profit margin of 8.0% (+1.5 percentage points YoY) [2] - The strong performance in non-IFRS net profit margin and operating profit margin is attributed to the increase in digital marketing revenue and controlled expenditure, leading to improved efficiency [2] - Despite being at a relatively high valuation, the company's strong growth potential provides fundamental support, and there is potential for valuation uplift in the short term due to favorable market sentiment [2] Earnings Forecast and Valuation - The company has adjusted its 2025 non-IFRS net profit forecast upward by 9% to 6.265 billion yuan, while maintaining the 2026 forecast at 6.310 billion yuan [2] - Based on the sum-of-the-parts (SOTP) valuation method, the target price has been raised by 5.9% to 71.4 HKD, indicating a potential upside of 10.7% [2]

Core Insights - JD Health reported Q3 2025 revenue of 17.12 billion yuan, a year-on-year increase of 28.7%, and a Non-IFRS net profit of 1.9 billion yuan, up 42.4% year-on-year [1] - During this year's "Double 11" shopping festival, JD Health's nutrition and health segment saw transaction volume from over 2,500 brands double year-on-year, with nearly 100 subcategories also experiencing 100% growth [3] Group 1 - JD Health is leveraging a dual-driven model of "super pharmaceutical supply chain + professional medical health services" to achieve significant growth [3] - The company is focusing on two trends in China's nutrition consumption: a shift from "general health" to "precise nutrition" and a move from "blind following" to "rational decision-making" among consumers [3] - JD Health has established a quality barrier through high-standard product selection and industry standard co-construction, enabling consumers to make informed choices [3] Group 2 - JD Health has formed a professional nutritionist team to provide scientific nutrition knowledge through live broadcasts and online consultations, addressing consumer decision-making anxiety [4] - The introduction of an "AI nutritionist" has allowed for 24/7 personalized nutrition consultations, with over 90% of online inquiries during "Double 11" handled by AI [4] - The company aims to deepen its supply chain layout and integrate global quality nutrition products with professional services to drive the nutrition and health industry towards standardization and precision [4]

Core Insights - JD Health's performance during the 11.11 shopping festival demonstrated significant growth, with over 2,500 health and nutrition brands achieving a doubling of transaction volume year-on-year, and nearly 100 subcategories also seeing a 100% increase in sales [1] - The company reported a strong third-quarter performance, with revenues reaching 17.12 billion yuan, a year-on-year increase of 28.7%, and a Non-IFRS net profit of 1.9 billion yuan, up 42.4% [1] - JD Health launched over 30 new specialty drugs during the reporting period, reinforcing its position as the leading platform for the online debut of new specialty drugs [1] Business Developments - At the recent China International Import Expo, JD Health established multiple partnerships with nine global nutrition and health brands, including Noromega and NYO3, to introduce high-quality products to the Chinese market [2] - The company has formed a professional nutritionist team to provide scientific nutritional knowledge through live broadcasts and online consultations, enhancing consumer understanding [2] - The AI nutritionist has been implemented to handle over 90% of online consultations during the 11.11 period, covering more than 200 nutrition categories and providing personalized advice based on user data [2] Future Outlook - JD Health's management emphasized the vast potential of the health consumption market, indicating plans to deepen the super supply chain layout and integrate global quality nutrition products with professional services [3] - The company aims to drive the nutrition and health industry towards standardization and precision, providing better health solutions for consumers and sustaining growth momentum [3]